BTAI (BioXcel Therapeutics) Other Current Payables : $0.11 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Other Current Payables?

BioXcel Therapeutics's Other Current Payables for the quarter that ended in Sep. 2024 was $0.11 Mil.

BioXcel Therapeutics's quarterly Other Current Payables declined from Mar. 2024 ($0.12 Mil) to Jun. 2024 ($0.11 Mil) but then increased from Jun. 2024 ($0.11 Mil) to Sep. 2024 ($0.11 Mil).

BioXcel Therapeutics's annual Other Current Payables increased from Dec. 2021 ($0.20 Mil) to Dec. 2022 ($0.42 Mil) but then declined from Dec. 2022 ($0.42 Mil) to Dec. 2023 ($0.11 Mil).

BioXcel Therapeutics Other Current Payables Historical Data

The historical data trend for BioXcel Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Other Current Payables Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

0.06

0.16

0.20

0.42

0.11

BioXcel Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Current Payables	Get a 7-Day Free Trial															0.73	0.11	0.12	0.11	0.11

BioXcel Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

BioXcel Therapeutics Other Current Payables Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

BX2:Germany

Address

555 Long Wharf Drive, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Executives

Richard I Steinhart	officer: Chief Financial Officer	125 ELM STREET, NEW CANAAN CT 06840
Matthew T. Wiley	officer: CHIEF COMMERCIAL OFFICER	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Javier Rodriguez	officer: SEE REMARKS	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Frank Yocca	officer: Chief Scientific Officer	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vincent O'neill	officer: Chief Medical Officer	2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Vimal Mehta	director, officer: CEO, President, Secretary	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Krishnan Nandabalan	director, 10 percent owner	228 VILLAGE POND ROAD, GUILFORD CT 06437
Alka Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello	10 percent owner	10 TEMPLETON ROAD, WALLINGFORD CT 06492
Pardeep Kumar Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437